Quantcast
Last updated on April 16, 2014 at 7:25 EDT

Latest Surefire Medical Inc. Stories

2014-03-26 12:29:33

Study presented at SIR also concludes coiling can be eliminated or minimized with use of the technologically advanced Surefire Infusion System SAN DIEGO, March 26, 2014 /PRNewswire/ -- Surefire Medical, Inc. today announced that the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial, presented today at the Society for Interventional Radiology meeting in San Diego (SIR), showed significant reductions in fluoroscopy time, procedure time, radiation dose and contrast dose...

2014-03-13 08:27:58

WESTMINSTER, Colo., March 13, 2014 /PRNewswire/ -- Surefire Medical, Inc., developer of a new class of infusion systems designed to maximize direct-to-tumor drug delivery, announced today that the company has received 510(k) FDA clearance and the CE Mark for its enhanced line of Surefire Guiding Catheters used in radioembolization and chemoembolization procedures. Surefire's newest guiding catheters--Axis, Cobra1 and Simmons1--are designed to provide Interventional Radiologists and...

2013-12-11 08:29:17

Study evaluates eliminating coiling by using the novel anti-reflux Surefire Infusion System in radioembolization procedures WESTMINSTER, Colo., Dec. 11, 2013 /PRNewswire/ -- Surefire Medical, Inc. today announced that it has completed enrollment in the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial. This randomized prospective study investigates the feasibility and benefits of performing Selective Internal Radiation Therapy (SIRT), or radioembolization, without...

2013-10-18 08:24:14

Device Designed for Super Selective Embolization WESTMINSTER, Colo., Oct. 18, 2013 /PRNewswire/ -- Surefire Medical, Inc., today announced the launch of a new, enhanced infusion system - the Surefire Infusion System mT - designed to treat vessels as small as 2mm to 3.5mm in interventional direct-to-target embolization procedures. The mT incorporates Surefire's new low profile, effortlessly deployed expandable tip technology for maximum dose delivery without reflux. "The new Surefire Infusion...

2013-09-16 00:21:57

Six CIRSE presentations and posters confirm advantages of the Surefire Infusion System in cancer treatment WESTMINSTER, Colo., Sept. 16, 2013 /PRNewswire/ -- Surefire Medical, Inc., the developer of a brand new class of infusion systems designed to maximize direct-to-tumor drug delivery without reflux, today announced that presentations at the Cardiovascular and Interventional Radiological Society (CIRSE) meeting make the economic case for use of the new Surefire Infusion System (SIS)....

2013-07-10 08:26:32

May enable treatment of patients previously deemed untreatable WESTMINSTER, Colo., July 10, 2013 /PRNewswire/ -- Case reports published in the Journal of Cardiovascular and Interventional Radiology found that by using the Surefire Infusion System, radioembolization could be successfully performed without the need to protect nearby blood vessels, a significant advance that may enable doctors to safely extend liver cancer treatment to patients who were previously deemed untreatable....

2013-06-20 08:25:57

SYDNEY and WESTMINSTER, Colo., June 20, 2013 /PRNewswire/ -- Sirtex Medical Limited (ASX: SRX) and US-based Surefire Medical today announced a sales and marketing partnership to distribute Surefire's range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets. The agreement will see Sirtex exclusively distribute the Surefire Medical range of products in the company's rapidly growing Asia Pacific markets including Australia. Sirtex...

2013-05-02 08:35:15

Minimally invasive treatment as an alternative to bariatric surgery on the horizon WESTMINSTER, Colo., May 2, 2013 /PRNewswire/ -- Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced that the company's Surefire Infusion System will be used in the development of the first clinically viable microcatheter-based, minimally invasive treatment for obesity as an alternative to...

2013-04-13 23:03:40

Surefire Medical's first-in-class antireflux infusion system can accommodate smaller vessels and selective procedures in direct-to-tumor cancer treatment, and significantly increases penetration of embolics to 99.9 percent compared to 72.8 percent when using end-hole catheters. New Orleans, LA (PRWEB) April 13, 2013 Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced the launch...

2013-03-06 08:25:56

WESTMINSTER, Colo., March 6, 2013 /PRNewswire/ -- Surefire Medical's new infusion system maximizes delivery of drugs directly to the tumor site while minimizing potential damage to non-target organs, according to a new study. The ability to more safely and efficiently deliver embolic agents to target tumors locally marks a significant advance in radiation oncology procedures and in the treatment of liver cancer. The 29 procedure study, led by Steven Rose, M.D. of the University of...